Clinical trialNCT00689000CompletedPhase 1/PHASE2Interventional

Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)

SponsorChroma TherapeuticsEnrollment57Acute Myeloid LeukemiaMultiple MyelomaMyelodysplastic Syndrome

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is an open-label, non-randomised, multi-centre phase I-II study of CHR-2797 administered orally once a day. The study involves two distinct phases: * Phase I: an open-label, dose-escalating phase of the study to explore the safety, tolerability, and pharmacokinetics (PK) of CHR-2797. * Phase II: the recommended dose level of CHR-2797, as determined in phase I, will be administered to a further cohort of approximately 40 patients to determine whether CHR-2797 has sufficient biological activity against the disease(s) under study.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Alan Burnett, MD
University Hospital, Cardiff, United Kingdom
Principal Investigator
clinicaltrials.gov ↗
Bob Lowenberg, MD
Erasmus MC, Rotterdam
Principal Investigator
clinicaltrials.gov ↗
Carsten Müller-Tidow, MD
Universitätsklinikum, Münster, Germany
Principal Investigator
clinicaltrials.gov ↗
Gareth Morgan, MD
Royal Marsden Hospital, UK
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Gert Ossenkoppele, MD
Vrije Universiteit MC, Amsterdam
Principal Investigator
clinicaltrials.gov ↗
Michel Delforge, MD
UZ Gasthuisberg, Leuven, Belgium
Principal Investigator
clinicaltrials.gov ↗
Pierre Zachée, MD
ZNA Antwerpen, Belgium
Principal Investigator
clinicaltrials.gov ↗
Ulrich Dührsen, MD
Universitätsklinikum, Essen, Germany
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United Kingdom

Nexus Oncology Ltd
Edinburgh, Scotland, United Kingdom

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CHR-2797: Aminopeptidase inhibitor

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 May 2006
Primary completion: 31 Dec 2007
Completion: 31 Dec 2007
Last update posted: 22 Oct 2010
Registered enrollment: 57
Registry id: NCT00689000

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.